Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Systematic Review Article

The Effect of DPP-4i on Endothelial Function and Arterial Stiffness in Patients with Type 2 Diabetes: A Systematic Review of Randomized Placebo-controlled Trials

Author(s): Stavroula A. Paschou, Gerasimos Siasos*, Evanthia Bletsa, Panagiota K. Stampouloglou, Evangelos Oikonomou, Alexios S. Antonopoulos, Konstantinos Batzias, Vasiliki Tsigkou, Konstantinos Mourouzis, Andromachi Vryonidou, Nikolaos Tentolouris, Manolis Vavouranakis and Dimitrios Tousoulis

Volume 26, Issue 46, 2020

Page: [5980 - 5987] Pages: 8

DOI: 10.2174/1381612826666200417153241

Price: $65

Abstract

We systematically reviewed the literature regarding the impact of dipeptidyl peptidase-4 inhibitors (DPP-4i) on vascular function, including endothelial function and arterial stiffness, as predictors of atherosclerosis progression and cardiovascular disease in patients with type 2 diabetes mellitus (T2DM). We searched PubMed in order to identify clinical trials that investigated the effect of DPP-4i on vascular function in patients with T2DM when compared with placebo. Although 168 articles were initially found, only 6 studies (total 324 patients) investigated the effect of DPP-4i in comparison with placebo, specifically linagliptin and sitagliptin, and satisfied the inclusion criteria. There are scarce data to indicate that linagliptin may enhance endothelial function and exert a slight beneficial effect on arterial wall properties. Sitagliptin seems to have a neutral effect on these variables. Further trials are needed to elucidate the topic. The standards of reporting were in accordance with the PRISMA guidelines.

Keywords: Type 2 diabetes mellitus, DPP-4 inhibitors, endothelial function, arterial stiffness, cardiovascular health, molecular cardiology.

« Previous Next »
[1]
Avogaro A, de Kreutzenberg SV, Fadini G. Endothelial dysfunction: causes and consequences in patients with diabetes mellitus. Diabetes Res Clin Pract 2008; 82(82)(Suppl. 2): S94-S101.
[http://dx.doi.org/10.1016/j.diabres.2008.09.021] [PMID: 18954919]
[2]
Fox CS, Golden SH, Anderson C, et al. American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research; American Diabetes Association. Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care 2015; 38(9): 1777-803.
[http://dx.doi.org/10.2337/dci15-0012] [PMID: 26246459]
[3]
Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287(19): 2570-81.
[http://dx.doi.org/10.1001/jama.287.19.2570] [PMID: 12020339]
[4]
Nilsson J, Bengtsson E, Fredrikson GN, Björkbacka H. Inflammation and immunity in diabetic vascular complications. Curr Opin Lipidol 2008; 19(5): 519-24.
[http://dx.doi.org/10.1097/MOL.0b013e32830f47cd] [PMID: 18769234]
[5]
Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2018 executive summary. Endocr Pract 2018; 24(1): 91-120.
[http://dx.doi.org/10.4158/CS-2017-0153] [PMID: 29368965]
[6]
Luconi M, Cantini G, Ceriello A, Mannucci E. Perspectives on cardiovascular effects of incretin-based drugs: From bedside to bench, return trip. Int J Cardiol 2017; 241: 302-10.
[http://dx.doi.org/10.1016/j.ijcard.2017.02.126] [PMID: 28285800]
[7]
Karasik A, Aschner P, Katzeff H, Davies MJ, Stein PP. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. Curr Med Res Opin 2008; 24(2): 489-96.
[http://dx.doi.org/10.1185/030079908X261069] [PMID: 18182122]
[8]
Nyström T, Gutniak MK, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004; 287(6): E1209-15.
[http://dx.doi.org/10.1152/ajpendo.00237.2004] [PMID: 15353407]
[9]
Ida S, Murata K, Betou K, et al. Effect of trelagliptin on vascular endothelial functions and serum adiponectin level in patients with type 2 diabetes: a preliminary single-arm prospective pilot study. Cardiovasc Diabetol 2016; 15(1): 153.
[http://dx.doi.org/10.1186/s12933-016-0468-4] [PMID: 27809903]
[10]
Ayaori M, Iwakami N, Uto-Kondo H, et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc 2013; 2(1)e003277
[http://dx.doi.org/10.1161/JAHA.112.003277] [PMID: 23525426]
[11]
Leung M, Leung DY, Wong VW. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study. Diab Vasc Dis Res 2016; 13(3): 236-43.
[http://dx.doi.org/10.1177/1479164116629352] [PMID: 26993495]
[12]
Vlachopoulos C, Aznaouridis K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55(13): 1318-27.
[http://dx.doi.org/10.1016/j.jacc.2009.10.061] [PMID: 20338492]
[13]
Baltzis D, Dushay JR, Loader J, et al. Effect of Linagliptin on Vascular Function: A Randomized, Placebo-controlled Study. J Clin Endocrinol Metab 2016; 101(11): 4205-13.
[http://dx.doi.org/10.1210/jc.2016-2655] [PMID: 27583476]
[14]
Widlansky ME, Puppala VK, Suboc TM, et al. Impact of DPP-4 inhibition on acute and chronic endothelial function in humans with type 2 diabetes on background metformin therapy. Vasc Med 2017; 22(3): 189-96.
[http://dx.doi.org/10.1177/1358863X16681486] [PMID: 28145158]
[15]
de Boer SA, Heerspink HJL, Juárez Orozco LE, et al. Effect of linagliptin on pulse wave velocity in early type 2 diabetes: A randomized, double-blind, controlled 26-week trial (RELEASE). Diabetes Obes Metab 2017; 19(8): 1147-54.
[http://dx.doi.org/10.1111/dom.12925] [PMID: 28244635]
[16]
Smits MM, Tonneijck L, Muskiet MH, et al. The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients. Diabetes Res Clin Pract 2017; 124: 1-10.
[http://dx.doi.org/10.1016/j.diabres.2016.12.011] [PMID: 28086201]
[17]
Jax T, Stirban A, Terjung A, et al. A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes. Cardiovasc Diabetol 2017; 16(1): 13.
[http://dx.doi.org/10.1186/s12933-016-0493-3] [PMID: 28109295]
[18]
Hage C, Brismar K, Lundman P, Norhammar A, Rydén L, Mellbin L. The DPP-4 inhibitor sitagliptin and endothelial function in patients with acute coronary syndromes and newly detected glucose perturbations: A report from the BEGAMI study. Diab Vasc Dis Res 2014; 11(4): 290-3.
[http://dx.doi.org/10.1177/1479164114533355] [PMID: 24845072]
[19]
Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2015; 373(3): 232-42.
[http://dx.doi.org/10.1056/NEJMoa1501352] [PMID: 26052984]
[20]
Rosenstock J, Perkovic V, Johansen OE, et al. CARMELINA Investigators Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA 2019; 321(1): 69-79.
[http://dx.doi.org/10.1001/jama.2018.18269] [PMID: 30418475]
[21]
Rosenstock J, Kahn SE, Johansen OE, et al. Effect of Linagliptin vs. Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. JAMA 2019; 322(12): 1155-66.
[22]
Ras RT, Streppel MT, Draijer R, Zock PL. Flow-mediated dilation and cardiovascular risk prediction: a systematic review with meta-analysis. Int J Cardiol 2013; 168(1): 344-51.
[http://dx.doi.org/10.1016/j.ijcard.2012.09.047] [PMID: 23041097]
[23]
Tousoulis D, Androulakis E, Papageorgiou N, et al. Novel biomarkers assessing endothelial dysfunction: role of microRNAs. Curr Top Med Chem 2013; 13(13): 1518-26.
[http://dx.doi.org/10.2174/15680266113139990100] [PMID: 23745803]
[24]
Charakida M, de Groot E, Loukogeorgakis SP, et al. Variability and reproducibility of flow-mediated dilatation in a multicentre clinical trial. Eur Heart J 2013; 34(45): 3501-7.
[http://dx.doi.org/10.1093/eurheartj/eht223] [PMID: 23821401]
[25]
Siasos G, Gouliopoulos N, Moschos MM, et al. Role of endothelial dysfunction and arterial stiffness in the development of diabetic retinopathy. Diabetes Care 2015; 38(1): e9-e10.
[http://dx.doi.org/10.2337/dc14-1741] [PMID: 25538324]
[26]
Mitchell GF, Hwang SJ, Vasan RS, et al. Arterial stiffness and cardiovascular events: the Framingham Heart Study. Circulation 2010; 121(4): 505-11.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.109.886655] [PMID: 20083680]
[27]
Cavalcante JL, Lima JA, Redheuil A, Al-Mallah MH. Aortic stiffness: current understanding and future directions. J Am Coll Cardiol 2011; 57(14): 1511-22.
[http://dx.doi.org/10.1016/j.jacc.2010.12.017] [PMID: 21453829]
[28]
Chen CC, Hung KC, Hsieh IC, Wen MS. Association between peripheral vascular disease indexes and the numbers of vessels obstructed in patients with coronary artery disease. Am J Med Sci 2012; 343(1): 52-5.
[http://dx.doi.org/10.1097/MAJ.0b013e31821fec80] [PMID: 21709534]
[29]
Koska J, Sands M, Burciu C, Reaven P. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes. Diab Vasc Dis Res 2015; 12(3): 154-63.
[http://dx.doi.org/10.1177/1479164114562411] [PMID: 25852133]
[30]
Scheen AJ. Cardiovascular effects of gliptins. Nat Rev Cardiol 2013; 10(2): 73-84.
[http://dx.doi.org/10.1038/nrcardio.2012.183] [PMID: 23296071]
[31]
Takahashi M. Role of the SDF-1/CXCR4 system in myocardial infarction. Circ J 2010; 74(3): 418-23.
[http://dx.doi.org/10.1253/circj.CJ-09-1021] [PMID: 20118565]
[32]
Takahashi A, Ihara M, Yamazaki S, Asanuma H, Asakura M, Kitakaze M. Impact of Either GLP-1 Agonists or DPP-4 Inhibitors on Pathophysiology of Heart Failure. Int Heart J 2015; 56(4): 372-6.
[http://dx.doi.org/10.1536/ihj.15-028] [PMID: 26104180]
[33]
Shigeta T, Aoyama M, Bando YK, et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation 2012; 126(15): 1838-51.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.112.096479] [PMID: 23035207]
[34]
Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275(5302): 964-7.
[http://dx.doi.org/10.1126/science.275.5302.964] [PMID: 9020076]
[35]
Oliver JJ, Webb DJ, Newby DE. Stimulated tissue plasminogen activator release as a marker of endothelial function in humans. Arterioscler Thromb Vasc Biol 2005; 25(12): 2470-9.
[http://dx.doi.org/10.1161/01.ATV.0000189309.05924.88] [PMID: 16210566]

Rights & Permissions Print Cite
Article Metrics
16
© 2025 Bentham Science Publishers | Privacy Policy